Journal Article Review Epublish
PubMed: 40342999 DOI: 10.3389/fphar.2025.1598279
Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanisms.
Front Pharmacol 16:1598279
Authors: Jiqing Zhang, Dan Ouyang, Mu Liu, Yuting Xiang, Zhongjun Li
Affiliations
- The First Clinical Medical College, Guangdong Medical University, Zhanjiang, China. Department of Obstetrics and Gynecology, Dongguan People's Hospital, Dongguan, China.
- Department of Obstetrics and Gynecology, Dongguan People's Hospital, Dongguan, China.
Abstract
Ovarian cancer, a gynecologic malignancy with high mortality rates, faces persistent therapeutic challenges due to acquired resistance and frequent recurrence with conventional therapies. While poly (ADP-ribose) polymerase (PARP) inhibitors have primarily transformed clinical outcomes through the synthetic lethality mechanism, their long-term efficacy remains constrained by therapeutic resistance. Ferroptosis, a novel programmed cell death modality characterized by iron-dependent lipid peroxidation, has emerged as a promising therapeutic frontier in oncology. This review is the first to summarize the mechanisms of action and resistance associated with both ferroptosis and PARP inhibitors in ovarian cancer.
MeSH
Poly(Adp-Ribose) Polymerase Inhibitors, Poly(Adp-Ribose) Polymerases, Neoplasms, Synthetic Lethal Mutations, Ferroptosis, Poly Adenosine Diphosphate Ribose, Ovarian Neoplasms, Research, Therapeutics